Immune-mediated hemolytic anemia (IMHA) is anemia caused by the immune system making antibodies against its own red blood cells, which are then destroyed faster than the bone marrow can replace them. It happens in both people and animals. In human medicine it is usually called autoimmune hemolytic anemia (AIHA); the term IMHA is used most often by vets, because it is one of the most common serious blood diseases in dogs and also occurs in cats.
In every species the core features are the same: anemia, laboratory signs of red-cell destruction, and evidence of antibodies on the red cells, usually a positive Coombs test. Treatment suppresses the immune system, most often starting with steroids, and prevents blood clots, which are a major cause of death. The first sections below cover humans; there is a separate section on IMHA in dogs and cats.
What Happens in Immune-Mediated Hemolytic Anemia?
Red blood cells normally survive about 120 days. In IMHA, antibodies (IgG, IgM, or both) coat the cell surface and mark it for removal. How the cell is destroyed depends mostly on the antibody type.
Extravascular hemolysis
This is the more common route. IgG-coated red cells are recognized by macrophages in the spleen, which bite off pieces of membrane. The cell reseals as a smaller, rounder spherocyte that can no longer squeeze through the spleen and is eventually eaten whole. The liver clears cells heavily coated with complement. Because the breakdown happens inside cells, the main clues are jaundice and a raised bilirubin rather than red urine.
Intravascular hemolysis
When antibodies activate the full complement cascade, holes are punched in the membrane and the cell bursts inside the bloodstream. Free hemoglobin spills into the plasma and urine, giving dark, cola-colored urine (hemoglobinuria). This pattern is typical of IgM cold antibodies and paroxysmal cold hemoglobinuria, and it tends to be more abrupt and dangerous.
Primary vs secondary IMHA
Primary (idiopathic) IMHA has no identifiable trigger. Secondary IMHA is driven by something else, such as lupus, chronic lymphocytic leukemia or lymphoma, infections like Mycoplasma pneumoniae or Epstein-Barr virus, or drugs such as certain cephalosporins and penicillins, methyldopa, and fludarabine. Finding and treating a trigger can settle the hemolysis. Broader background is in our anemia guide.
Types of Autoimmune Hemolytic Anemia in Humans
| Type | Antibody | Temperature it binds best | Main site of destruction | Share of cases |
|---|---|---|---|---|
| Warm AIHA | IgG | Body temperature (37°C) | Spleen (extravascular) | Most cases, roughly three-quarters |
| Cold agglutinin disease | IgM | Cold (below body temperature) | Liver; intravascular in flares | Most of the rest |
| Mixed type | IgG and IgM | Both | Both | Uncommon |
| Paroxysmal cold hemoglobinuria | IgG (Donath-Landsteiner) | Binds in cold, lyses when warmed | Intravascular | Rare; mostly children after a viral illness |
| Drug-induced immune hemolysis | Varies | Varies | Either | Rare |
The type matters because treatment differs. Warm autoimmune hemolytic anemia usually responds to steroids; cold agglutinin disease generally does not.
Symptoms
Symptoms reflect how fast the hemoglobin falls. A slow decline may cause only tiredness; a rapid one can be an emergency.
- Fatigue, weakness, and breathlessness on exertion
- Pale skin and a fast heart rate
- Jaundice (yellow skin or eyes)
- Dark urine, especially in intravascular hemolysis
- An enlarged spleen in some patients
- In cold agglutinin disease, blue or painful fingers, toes, ears, or nose in the cold
How IMHA Is Diagnosed
Diagnosis rests on three things: confirmed anemia, proof that red cells are being destroyed, and evidence that the destruction is immune. The usual sequence works like this:
- Confirm anemia on a complete blood count.
- Check the marrow response with a reticulocyte count. It is usually high, but a low count does not rule IMHA out; the antibodies can also target young cells.
- Look for hemolysis: raised LDH and indirect bilirubin, low or absent haptoglobin, and hemoglobin in the urine if lysis is intravascular.
- Examine the blood smear for spherocytes (warm type) or clumped red cells (cold type).
- Prove the immune cause with the direct antiglobulin test and, where relevant, agglutination testing.
- Search for a secondary cause: medication review, autoimmune serology, imaging, and flow cytometry for lymphoproliferative disease.
| Test | Typical result in IMHA | What it tells you |
|---|---|---|
| Hemoglobin | Low; may be dangerously low at presentation | Severity of anemia |
| Reticulocytes | Usually raised | Marrow is trying to compensate |
| LDH | Raised | Red-cell breakdown |
| Haptoglobin | Low or undetectable | Free hemoglobin is being mopped up |
| Indirect bilirubin | Raised | Hemoglobin breakdown |
| Blood smear | Spherocytes, polychromasia, agglutination | Pattern of immune destruction |
| Direct antiglobulin (Coombs) test | Positive for IgG, C3d, or both | Antibody or complement on the red cells |
Coombs testing and agglutination tests
The direct antiglobulin test (DAT), or direct Coombs test, adds anti-human antibody to washed red cells. If the cells are already coated with IgG or complement, they clump. An IgG-positive pattern points to warm AIHA; a C3d-only pattern points to cold agglutinin disease.
When the red cells visibly clump on their own, a saline agglutination test helps. A drop of blood is mixed with saline: rouleaux (stacked cells) disperse, but true immune agglutination persists. Persistent agglutination supports IMHA on its own. It is a standard test in veterinary practice, and in human labs visible autoagglutination is a strong clue to cold agglutinins, confirmed by measuring the cold agglutinin titer.
A small minority of genuine cases are DAT-negative because the antibody level is below the test’s detection limit. More sensitive methods can sometimes find them.
Treatment for IMHA in Humans
First-line: corticosteroids
For warm AIHA, prednisone at about 1 mg/kg per day is the standard starting treatment, and most patients respond within a few weeks. The dose is then tapered slowly over months. Stopping too quickly is a common cause of relapse.
Rituximab
Rituximab, an antibody against the CD20 protein on B cells, is now the usual second-line treatment and is sometimes given with steroids from the start. A common schedule is 375 mg/m² weekly for four weeks. It is also the backbone of drug treatment for cold agglutinin disease.
Other immunosuppressants
- Azathioprine: steroid-sparing; works slowly over months
- Mycophenolate mofetil: steroid-sparing maintenance option
- Cyclosporine: used in refractory warm AIHA
- Cyclophosphamide: reserved for difficult cases
Splenectomy
Removing the spleen takes away the main site of destruction in warm AIHA. It was the traditional second-line option and still works for some patients, but it has become less common since rituximab and brings a lifelong risk of serious infection. It does not help cold agglutinin disease, where the liver does most of the clearing.
Severe or refractory disease
Blood transfusion should not be withheld from a patient with life-threatening anemia just because crossmatching is difficult; the blood bank provides the “least incompatible” units. Intravenous immunoglobulin can buy time. For cold agglutinin disease, keeping warm is real treatment, and sutimlimab, a complement C1s inhibitor, was approved in the US in 2022.
Blood Clots: Why IMHA Causes Thrombosis
This is the complication people least expect. Anemia sounds like a bleeding problem, yet IMHA makes the blood more likely to clot, in both humans and animals. Deep vein thrombosis, pulmonary embolism, and clots in unusual sites such as the portal vein are all seen, mostly during active hemolysis.
Several mechanisms combine:
- Free hemoglobin released from destroyed cells mops up nitric oxide, which normally keeps vessels relaxed and platelets calm.
- Damaged red cell membranes expose phosphatidylserine, a surface that speeds up clotting reactions.
- Inflammation switches on tissue factor and activates platelets and the vessel lining.
- Complement activation adds further platelet and endothelial activation.
- Hospital treatment brings its own risks: bed rest, central lines, and high-dose steroids.
For this reason many hematologists give preventive anticoagulation, typically low-molecular-weight heparin, to hospitalized patients with active hemolysis unless bleeding risk is high. In dogs, clot prevention is now part of standard IMHA care, and thromboembolism is considered one of the leading causes of death.
Prognosis: Survival, Relapse, and Long-Term Outlook
In humans, most people with warm AIHA respond to first-line treatment, and deaths are uncommon with modern care. The main problems are relapse, which is common after steroids are stopped, and complications of long-term immunosuppression such as infection, diabetes, and bone loss. Secondary IMHA often improves when the underlying disease is controlled. Cold agglutinin disease tends to be chronic, with flares in winter or during infections. Many patients stay in long remissions; others need low-dose maintenance treatment for years.
Worse outcomes are linked to very low hemoglobin at diagnosis, a low reticulocyte count, intravascular hemolysis, thrombosis, and serious underlying disease. In dogs the outlook is more guarded: the first two weeks after diagnosis carry the highest risk, and death is most often due to thromboembolism or uncontrolled anemia. Dogs that survive the first weeks often do well, although relapse is possible.
IMHA in Dogs and Cats
If you searched this term because of your pet, the underlying disease is the same, but causes, testing, and drug choices differ. Your vet is the right person to guide treatment. This section summarizes the key points.
Dogs
Most canine IMHA is primary, with no trigger found. Cocker spaniels are the classic predisposed breed, with springer spaniels, poodles, Old English sheepdogs, and Irish setters also overrepresented, and middle-aged females more commonly affected. Secondary causes include tick-borne infections such as Babesia, certain drugs, and cancer. Signs include sudden weakness, pale or yellow gums, rapid breathing, dark urine, and collapse.
Vets diagnose it with a blood count, smear for spherocytes, the saline agglutination test, and a canine Coombs test, and they screen for infections and tumors. Treatment is usually prednisolone plus a second immunosuppressant such as mycophenolate, azathioprine, or cyclosporine, blood transfusion when needed, and anticlotting drugs such as clopidogrel, rivaroxaban, or heparin.
Cats
IMHA is less common in cats and more often secondary, particularly to the blood parasite Mycoplasma haemofelis or feline leukemia virus. Cats often show lethargy and poor appetite rather than dramatic collapse. Azathioprine is generally avoided in cats because they tolerate it poorly.
| Feature | Humans (AIHA) | Dogs | Cats |
|---|---|---|---|
| Usual name | Autoimmune hemolytic anemia | IMHA | IMHA |
| Most cases | About half primary, half secondary | Mostly primary | Often secondary |
| Common triggers | Lupus, CLL, lymphoma, infections, drugs | Babesia, drugs, cancer | Mycoplasma haemofelis, FeLV |
| First-line drug | Prednisone | Prednisolone | Prednisolone |
| Main danger | Severe anemia, thrombosis, relapse | Thromboembolism in the first weeks | Underlying infection, severe anemia |
When to See a Doctor
Go to the emergency department for sudden severe fatigue with jaundice, dark or cola-colored urine, a racing heart at rest, fainting, or chest pain. If you already have IMHA, sudden leg swelling, chest pain, or breathlessness can mean a blood clot and needs urgent care. Contact your hematologist for returning tiredness or jaundice, which may mean relapse. For a pet with pale gums, weakness, or dark urine, see a vet the same day.
Frequently Asked Questions
Is IMHA the same as autoimmune hemolytic anemia?
Essentially yes. IMHA is the broader term and includes drug-induced and alloimmune forms, but in practice it usually means the autoimmune type. Human doctors say AIHA; vets say IMHA.
Is IMHA the same in humans and animals?
The mechanism is the same: antibodies against red cells, destruction in the spleen or bloodstream, and a risk of clots. Causes, predisposed groups, and some drugs differ, and the outlook in dogs is more guarded.
What causes IMHA in dogs?
Most often no cause is found. Known triggers include tick-borne infections, some medications, and cancer, and certain breeds such as cocker spaniels have an inherited tendency.
Why do IMHA patients get blood clots?
Destroyed red cells release free hemoglobin and pro-clotting membrane fragments, and inflammation activates platelets and the vessel lining. That is why preventive blood thinners are often used during active disease.
What is the survival rate for IMHA?
In humans, most people survive with treatment, although relapses are common. In dogs, the first two weeks are the most dangerous, and dogs that get through them often recover well.
Can a negative Coombs test rule out IMHA?
Not completely. A minority of cases are Coombs-negative because too few antibodies sit on each red cell for the test to detect. The diagnosis then relies on the overall picture and more sensitive tests.
